Spectral Ai, Inc. (MDAI) Stock Price & Analysis

Spectral Ai, Inc. (MDAI) fell 1.24% to USD 1.59 as of September 9, 2026 at 16:08 UTC, according to Nexqual real-time market data.

MDAI last closed at USD 1.59; the session ranged USD 1.58–1.63 on volume of 32,086 shares. Market capitalization is —, with a 52-week range of USD 1.18–2.97 (NCM). Source: Nexqual, September 9, 2026 at 16:08 UTC.

Key Statistics (as of September 9, 2026 at 16:08 UTC)

Technical Analysis (MDAI)

Nexqual's technical model rates MDAI "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 9, 2026 at 16:08 UTC.

From Spectral Ai, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)

Key Strengths & Strategy (as disclosed to the SEC)

• In addition to our validation study, we have conducted three large clinical studies with multiple sites across the United States, enrolling more than 400 patients, including both adult and pediatric burn patients.    2   Our proprietary and clinically validated database for burns is comprised of over 340 billion pixels of image data.
• Our DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation.
• In 2026, we hope that our full DeepView System may achieve Class II medical device designation with the United States Food and Drug Administration (FDA) via the De Novo application the Company submitted in June of 2025.
• Our DeepView System's proprietary optics can extract millions of pixels of data or AI model features from each group of raw images.

Partnerships

• On September 27, 2023, the Company executed a new contract with BARDA, providing the Company with additional funding of up to $150.0 million, including an initial award of approximately $54.9 million to support the clinical validation and application for FDA De Novo status of our DeepView AI-Burn software.
• In April 2023, we were awarded a $4.0 million grant from the Medical Technology Enterprise Consortium ("MTEC"), a 501I(3) biomedical technology consortium working in partnership with the Department of Defense, to develop our DeepView SnapShot M device in a Phase III feasibility and commercialization study.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 16:08 UTC. This page is informational and not investment advice.